Share price · MLTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MLTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+7.6%
Nothing announced by MLTX that day or the session before.
- 9 Nov 2026+9.5%
Nothing announced by MLTX that day or the session before.
- 22 Oct 2026+15.9%
Nothing announced by MLTX that day or the session before.
- 24 Sep 2026-6.0%
Nothing announced by MLTX that day or the session before.
- 9 Sep 2026-8.2%
Nothing announced by MLTX that day or the session before.
- 24 Jun 2026-5.7%
- 22 Jun 2026+15.4%
- 21 May 2026+8.3%
Nothing announced by MLTX that day or the session before.
- 11 May 2026+10.4%
- 1 Apr 2026-11.4%
Nothing announced by MLTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of MLTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | IL-17A/FAntibody-derived scaffold | Psoriatic ArthritisPsoriasisHidradenitis Suppurativa |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $69M | $383M+ $119M short-term inv. | $80M-$63M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $50M | $478M+ $59M short-term inv. | $62M-$56M operating cash flow | report ↗ |
| 2026-Q1 | — | $55M | $298M+ $59M short-term inv. | $70M-$66M operating cash flow | report ↗ |
| 2025-Q3 | — | $61M | $351M+ $30M short-term inv. | $70M-$45M operating cash flow | report ↗ |
| 2025-Q2 | — | $50M | $307M+ $118M short-term inv. | $55M-$55M operating cash flow | report ↗ |
| 2025-Q1 | — | $36M | $272M+ $209M short-term inv. | $40M-$38M operating cash flow | report ↗ |
| 2024-Q3 | — | $36M | $376M+ $118M short-term inv. | $35M-$25M operating cash flow | report ↗ |
| 2024-Q2 | — | $24M | $343M+ $177M short-term inv. | $24M-$28M operating cash flow | report ↗ |
| 2024-Q1 | — | $13M | $458M+ $89M short-term inv. | $14M-$15M operating cash flow | report ↗ |
| 2023-Q3 | — | $7.6M | $318M+ $178M short-term inv. | $9.4M-$9.3M operating cash flow | report ↗ |
| 2023-Q2 | — | $8.7M | $502M+ $0 short-term inv. | $10M-$12M operating cash flow | report ↗ |
| 2023-Q1 | — | $7.4M | $50M+ $13M short-term inv. | $9.0M-$9.0M operating cash flow | report ↗ |
| 2022-Q3 | — | $9.0M | $41M+ $42M short-term inv. | $10M-$9.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $11M | $93M | $12M-$34M operating cash flow | report ↗ |
| 2022-Q1 | — | $10M | $101M | $2.7M-$0.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $0.7M | $0.5M | $2.1M-$0.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $203M | $335M+ $59M short-term inv. | $57M-$196M operating cash flow | report ↗ |
MoonLake did not disclose revenue. R&D spend was $202.86M, up 79.9% YoY from $112.77M, while cash and equivalents stood at $334.52M, with cash, equivalents and short-term marketable debt securities of $394.0M at year-end. The company reported a net loss of $227.32M and a quarterly net burn of $227.32M.
MoonLake announced positive topline results from the Phase 2 S-OLARIS trial of sonelokimab in axial spondyloarthritis, with 81% of patients achieving ASAS40 by Week 12 and similar improvements in ASDAS-CRP and SPARCC MRI scores. The company also amended its Hercules Capital debt facility with a concurrent $25M drawdown, leaving up to $400M in non-dilutive funds available, and expects cash plus proceeds from a $75M equity raise to fund operations into the second half of 2027. Upcoming milestones include 52-week VELA-1 and VELA-2 data in Q2 2026, IZAR-1 and VELA-TEEN readouts in mid-2026, and a planned H2 2026 BLA submission for hidradenitis suppurativa, alongside IZAR-2 results in H2 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $113M | $180M+ $268M short-term inv. | $30M-$117M operating cash flow | report ↗ |
| 2023-FY | — | $32M | $451M+ $60M short-term inv. | $9.0M-$43M operating cash flow | report ↗ |
| 2022-FY | — | $42M | $40M+ $33M short-term inv. | $12M-$56M operating cash flow | report ↗ |
| 2021-FY | — | — | $8.0M+ $0 short-term inv. | $1.1M-$0.6M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 27 sales ($83.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-27 | Reich Kristian · Chief Scientific Officer | Open-market sale | 1,100 | $20.00 | $22K | Form 4 |
| 2026-07-22 | Reich Kristian · Chief Scientific Officer | Open-market sale | 2,448 | $20.00 | $49K | Form 4 |
| 2026-07-21 | Reich Kristian · Chief Scientific Officer | Open-market sale | 50,000 | $20.02 | $1.0M | Form 4 |
| 2026-07-20 | Reich Kristian · Chief Scientific Officer | Open-market sale | 43,700 | $20.09 | $878K | Form 4 |
| 2026-07-15 | Reich Kristian · Chief Scientific Officer | Open-market sale | 16,105 | $20.01 | $322K | Form 4 |
| 2026-07-10 | Santos da Silva Jorge · director, Chief Executive Officer | Open-market sale | 68,289 | $20.02 | $1.4M | Form 4 |
| 2026-07-09 | Santos da Silva Jorge · director, Chief Executive Officer | Open-market sale | 33,936 | $20.01 | $679K | Form 4 |
| 2026-07-01 | Santos da Silva Jorge · director, Chief Executive Officer | Open-market sale | 47,775 | $20.03 | $957K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 146 reporting institutions held 63.3M shares ($1.1B, 78.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BVF INC/IL | 16,001,284 | $298.3M |
| 2 | Deep Track Capital, LP | 6,408,863 | $119.5M |
| 3 | Cormorant Asset Management, LP | 4,480,433 | $83.5M |
| 4 | JANUS HENDERSON GROUP PLC | 3,451,628 | $64.3M |
| 5 | D. E. Shaw & Co., Inc. | 2,390,661 | $44.6M |
| 6 | MPM BIOIMPACT LLC | 1,811,082 | $33.8M |
| 7 | Weiss Asset Management LP | 1,708,328 | $31.8M |
| 8 | Logos Global Management LP | 1,500,000 | $28.0M |
| 9 | Point72 Asset Management, L.P. | 1,368,518 | $25.5M |
| 10 | CITADEL ADVISORS LLC | 1,323,728 | $24.7M |
| 11 | GOLDMAN SACHS GROUP INC | 1,130,233 | $21.1M |
| 12 | TWO SIGMA INVESTMENTS, LP | 1,122,312 | $20.9M |
| 13 | Balyasny Asset Management L.P. | 1,065,610 | $19.9M |
| 14 | BlackRock, Inc. | 1,021,851 | $19.0M |
| 15 | Vivo Capital, LLC | 1,000,000 | $18.6M |